We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BRAFV600E

News List

Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC pharmaceutical-business-review
June 08, 2020
Pierre Fabre has secured approval from the European Commission (EC) for Braftovi (encorafenib) plus cetuximab (Erbitux) to treat adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
EU nod for new metastatic colorectal cancer combination pharmatimes
June 05, 2020
Pierre Fabre's Braftovi (encorafenib) has been approved in Europe for use alongside Erbitux (cetuximab) to treat of adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.